The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes-Reference-Cited by-同舟云学术

The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes

Published:2017-07-18 Issue:6 Volume:57 Page:651-658
ISSN:0004-8666
Container-title:Australian and New Zealand Journal of Obstetrics and Gynaecology
language:en
Short-container-title:Aust N Z J Obstet Gynaecol

Author:

Nicklin James L.¹²^ORCID,McGrath Shaun¹,Tripcony Lee³,Garrett Andrea¹,Land Russell¹²,Tang Amy¹,Perrin Lewis¹⁴,Chetty Naven¹⁴,Jagasia Nisha¹,Crandon Alex J.¹⁴,Nascimento Marcelo¹⁵,Walker Graeme¹⁵,Sanday Karen¹,Obermair Andreas¹⁶

Affiliation:

1. Queensland Centre for Gynaecological Cancer; Brisbane Queensland Australia

2. School of Medicine, Obstetrics and Gynaecology; University of Queensland; Brisbane Queensland Australia

3. Cancer Care Services; Royal Brisbane and Women's Hospital; Brisbane Queensland Australia

4. Mater Adult Hospital; South Brisbane Queensland Australia

5. Gold Coast University Hospital; Southport Queensland Australia

6. Centre for Clinical Research; The University of Queensland; Brisbane Queensland Australia

Publisher

Wiley

Subject

Obstetrics and Gynecology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajo.12665/fullpdf

Reference13 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study;Dahm-Kahler;Gynecol Oncol,2016

3. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010

4. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602;Onda;J Clin Oncol

5. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial;Kehoe;Lancet,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of gated FDG PET/CT on the staging of patients with suspected or proven newly diagnosed advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer: results from a non-randomized, phase II clinical trial;International Journal of Gynecologic Cancer;2024-09-04

2. Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan;Journal of the Formosan Medical Association;2024-03

3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years’ experience;BMC Surgery;2022-09-12

4. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction;Diagnostics;2022-04-14

5. New therapeutic opportunities for women with low-grade serous ovarian cancer;Endocrine-Related Cancer;2022-01-01